Floatz logo

Teverelix Dp

GnRH Antagonist

Antev Ltd.Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the GnRH Antagonist cohort.

Asset / SponsorPhaseRating
Medroxyprogesterone acetate
ShangHai Ji Ai Genetics & IVF Institute
Phase 3B
TEVERELIX
Antev Ltd.
Phase 2CCC

Same molecule, other indications

Teverelix Dp is also rated in:

prostate cancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →